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Abstract
Extracellular vesicles (EVs) are membrane-bound vesicles released into the extracellular space by almost all types of cells. EVs
can cross the physiological barriers, and a variety of biological fluids are enriched in them. EVs are a heterogeneous population of
vesicles, including exosomes, microvesicles, and apoptotic bodies. The different subpopulations of vesicles can be differentiated
by size and origin, in which exosomes (~100 nm and from endocytic origin) are the most studied so far. EVs have essential roles
in cell-to-cell communication and are critical modulators of immune response under normal and pathological conditions.
Pregnancy is a unique situation of immune-modulation in which the maternal immune system protects the fetus from allogenic
rejection and maintains the immunosurveillance. The placenta is a vital organ that performs a multitude of functions to support
the pregnancy. The EVs derived from the human placenta have crucial roles in regulating the maternal immune response for
successful pregnancy outcome. Placenta-derived vesicles perform a myriad of functions like suppression of immune reaction to
the developing fetus and establishment and maintenance of a systemic inflammatory response to combat infectious intruders. A
fine-tuning of these mechanisms is quintessential for successful completion of pregnancy and healthy outcome for mother and
fetus. Dysregulation in the mechanisms mentioned above can lead to several pregnancy disorders. In this review, we summarize
the current literature regarding the critical roles played by the EVs in immunomodulation during pregnancy with particular
attention to the placenta-derived exosomes.
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Introduction
Pregnancy is a unique situation of immunomodulation in
which the maternal immune system adapts itself with the
semi-allogenic fetus and maintains its efficiency to fight
against the external pathogens. This has been achieved by
expressing a unique array of antigen presenting molecules at
the maternal-fetal interface and alteration of cytokine profile
from Th1 to Th2, thereby skewing the immunity from
cell-mediated to adaptive, with increased numbers of regula-
tory T cells [47, 62].
It has been proposed that factors released from placenta can
mediate the immunological adaptations in pregnancy [74].
Hormones, cytokines, and protein factors derived from pla-
centa mediate this [17]. The shedding of microparticles, re-
ferred to as Btrophoblast debri^ is a classical feature of preg-
nancy and these microparticles are reported to affect the sys-
temic inflammatory response in mother [1, 15]. The particles
shed from the placenta are predominantly EVs, which are
membrane-bound vesicles released from the cell into the ex-
tracellular space and immense literature implicates them as
important mediators of intercellular communication (reviewed
in [53]).
Depending upon the morphology and the biosynthetic
mechanism responsible for their origin, there are basically
three types of EVs, namely apoptotic bodies, microvesicles
(MVs), and exosomes [20]. Apoptotic bodies originate from
the apoptotic bleb and are approximately 800 nm to 5 μm in
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size, whereas MVs which are 50 to 1000 nm in diameter
originate from the outward budding of the plasma membrane.
Exosomes are 40-120 nm in diameter, originating from the
endosomal pathway in the cell and secreted into the extracel-
lular space [59]. A proper discrimination between the different
populations of EVs is challenging due to lack of better knowl-
edge regarding the precise mechanisms of their biogenesis and
secretion as well as the limitations of existing methods to
isolate pure populations of a single vesicle type.
EVs are important modulators of immune response and
play diverse roles in the immune system by interacting with
various immune cells and transferring information between
them [90]. The secretion of EVs from placenta is therefore
considered to be a potential mechanism by which maternal
immune system is modulated [58]. In this review, we aim to
summarize the recent literature of EVs in pregnancy, most
importantly exosomes derived from placenta and their vital
roles in immunological adaptations in pregnancy.
EVs as critical players in immune-modulation
Formerly, EVs were considered as mere Bgarbage bags^ to get
rid of waste products from the cell. The first report of EVs as
messenger vehicles came when [72] described that MHC
Class II molecules are enriched in the late endosomal com-
partments of B cells and is secreted via exosomes eliciting T
cell response. Following this, [100] reported the release of
exosomes from the dendritic cells modulating anti-tumor re-
sponse in murine models. Currently, substantial literature un-
veils the myriad of roles played by these endosomal vesicles
in diverse aspects of immune response such as antigen presen-
tation via MHC-peptide complexes or bacterial or tumor anti-
gens; immune-suppression by ligand-receptor interaction or
transfer of immune-modulatory proteins and non-coding
RNAs between cells, thereby changing the phenotype of the
recipient cells (reviewed in [18]).
Apart from exosomes, other EV populations like MVs are
also involved in eliciting immune response. MVs derived
from immune cells were studied for their role in promoting
immune response in bacterial infection [34] as well as in me-
diating the survival and proliferation of other immune cells
[26]. Interestingly, MVs released from placenta as well as
maternal immune cells are reported to be key players in acti-
vating leucocytes [52, 82] as well as maintaining the compe-
tency of maternal immune system to fight against external
invading organisms for successful pregnancy outcome [31,
63]. While studying the EVs and their implications on phys-
iological systems, exosomes are versatile due to its endosomal
origin and ability to selectively package the molecular cargo
[98], with immense body of literature delineating its potential
roles in intercellular communication (reviewed in [20, 89]).
Exosomes—new paradigm for intercellular
communication
Intercellular communication is critical for the growth and de-
velopment of organisms and is a major player in mediating
various physiological and pathological events in the body.
Since long time, the purview of intercellular communication
involved cell signaling mediated by soluble protein factors
like hormones, cytokines, and chemokines in paracrine and
autocrine manner, cell-to-cell contact, and the formation of
specialized gap junctions and tunneling nanotubes mediating
this (reviewed in [13]). The knowledge of exosomes as
cell-to-cell communicator opened new pathways for under-
standing cell signaling and currently identified as a novel
and efficient way of intercellular communication.
Exosomes are formed from the intra-luminal vesicles
(ILVs) encapsulated inside the multi-vesicular bodies
(MVBs) formed during endosomal maturation. MVBs and
ILVs are formed by the inward invagination of the late
endosomal membranes sequestering specific molecular cargo
that are sorted into the lumen of the ILVs (reviewed in [89]). A
highly conserved group of protein complex named exosome
sorting complex required for transport (ESCRT) helps in
membrane remodeling, formation of MVBs and ILVs, and
sorting of proteins into the ILVs. Different sub-complexes of
the ESCRT machinery like ESCRT-0, I, II, and III works in a
coordinated manner to promote vesicle budding and recruits
the ubiquitinated proteins into the ILVs. Common exosome
markers ALIX and TSG101 are integral part of the ESCRT
machinery [11, 19]. An ESCRT-independent mechanism in-
volving invagination of the ceramide-rich micro domains of
the endosomal membrane, organized by tetraspanins like
CD9, CD63, and CD81 and heat shock proteins, is also de-
scribed [55, 84, 95]. Interestingly, exosomes are enriched in
specific set of RNAs and the incorporation of RNAs into the
ILVs is mediated by RNA loading proteins (reviewed in [98]).
The heterogeneous ribonucleoprotein A2B1 (hnRNPA2B1)
has been implicated in the sorting of miRNAs into the ILVs
[97]. The MVBs are trafficked across the cytoskeletal frame-
work and docked to the plasma membrane by the RAB
GTPase family of proteins. Several different RABs are in-
volved in trafficking MVBs-containing ILVs of different mat-
uration stages and proteins belonging to the soluble NSF at-
tachment protein receptor (SNARE) complex mediate the fu-
sion of MVBs with the plasma membrane. The existence of
disparate mechanisms of exosome biogenesis and secretion
explains the coexistence of heterogeneous populations of
MVBs within the cells and different MVBs giving rise to
different sub-populations of exosomes (reviewed in [42])
(Fig. 1).
Exosomes are enriched in cytosolic andmembrane-associated
proteins, nucleic acids including mRNAs, non-coding
RNAs (most importantly miRNAs), small fragments of
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DNA and lipids. The molecular cargo of exosomes repre-
sents their cell of origin and these potential biological
signals are conveyed to cells located proximally and dis-
tally without the requirement for cell-to-cell contact.
Exosomes can permeate through different biological bar-
riers like the endothelial barrier [4] and blood-brain bar-
rier [2] and gain access to various biological fluids [5,
45]. The targeting of exosome to specific recipient cells in-
volve the presence of receptors on the surface of exosome and
recipient cell, followed by classical receptor-ligand interac-
tion. In certain modes of signaling, this receptor-ligand inter-
action is sufficient in activating the downstream signaling
pathways influencing the recipient cell function [7, 81]. In
other situations, this interaction promotes the internalization
of exosomes by recipient cells using different mechanisms
like phagocytosis, clathrin-mediated endocytosis,
caveolin-dependent endocytosis, micropinocytosis, and lipid
raft-mediated uptake (reviewed in [64]). Also, direct fusion of
exosomal membrane with the cell membrane and delivering
their contents inside the cell has been reported [61, 69].
Exosome signaling pathways are associated with several
important aspects of immune-regulation including immune
activation and immune-suppression [18]. Pregnancy is a
unique state of immune-modulation in which the maternal
immune system transiently tolerates the paternal antigens of
the semi-allogenic fetus, meanwhile protecting the body
against external pathogens [62]. EVs including exosomes play
significant roles in modulating the maternal immunity for suc-
cessful pregnancy.
Pregnancy and immune-modulation
Immune-tolerance to the developing fetus is a distinctive fea-
ture of normal healthy pregnancy and several factors like the
anatomical barrier between the mother and fetus, immaturity
Fig. 1 Formation and release of four sub-populations of EVs from
synctiotrophoblasts and exosome signaling in target cell. Exosomes
(~30–100 nm) are formed from the endosomal pathway and enriched in
proteins and non-coding RNA. ESCRT-dependent and -independent
mechanisms are involved in the biogenesis of exosomes. In the target
cell, exosome mediate downstream signaling by different methods: (1)
receptor-ligand interaction, (2) uptake by phagocytosis/ lipid raft-
mediated uptake, (3) endocytosis by clathrin/ caveolin-coated pits, and
(4) direct fusion of the exosomal membrane and release of content.
Synctiotrophoblast also releases microvesicles (100 nm–1 μm), formed
by the direct budding from the cell membrane, syncytial nuclear aggre-
gates (20–500 μm) with aggregates of aging nuclei, and apoptotic bodies
(1–4 μm) from cells undergoing apoptosis
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of the fetal immune system, and immune-suppressive state of
maternal system have been attributed to this [12]. But, recent
literature reveals that distinct immunological adaptations char-
acterize different stages of gestation and synchronize the
maternal-fetal tolerance with the systemic immune response
[62]. The immunological junction between the mother and the
fetus is composed of the maternal decidual cells that develop
from the endometrium and the fetal trophoblast cells with
three distinct sub-populations, namely the cytotrophoblasts,
multi-nucleated synctiotrophoblasts (STBs), and the invasive
extra-villous trophoblasts (EVTs). The maternal immune cells
at the feto-maternal interface are composed of 60–70% natural
killer (NK) cells, 20–30% monocytes/macrophages, 10–15%
T lymphocytes, and 1% dendritic cells (DCs) with sparse B
cell population [77].
Trophoblast cells are one of the rare cells in the
human body that is devoid of specific subsets of human
leucocytic antigens (HLAs) which help in promoting the
immune-tolerance of mother to fetal allograft. STBs and
villous cytotrophoblasts lack all the MHC Class I and
MHC Class II molecules, whereas the invasive EVTs
lack the HLA-A, HLA-B antigens, and the MHC Class
II antigens but express a unique array of MHC Class I
products, namely HLA-C, HLA-E, HLA-F, and HLA-G
[6]. This unique repertoire of HLA antigens in the tro-
phoblast cells selectively expresses the paternal antigens
and regulates their recognition by the innate immune
system and T cells. Hence, the lack of HLA-A and
HLA-B molecules by trophoblasts restricts the presenta-
tion of fetal antigens to the maternal immune cells and
the expression of HLA-C, HLA-E, HLA-G, and HLA-F
by EVTs interacts with specific ligand on the NK cells
and downregulates their cytotoxic function [60, 92].
Additionally, the maternal immunosurveillence against in-
fectious intruders is maintained by a deviation in the cytokine
profile from cell-mediated immunity, identified as Th1 to hu-
moral immunity, identified as Th2 (reviewed in [70]). The
main cytokines of the Th1 immunity are tumor necrosis factor
(TNF)- α, interferon (IFN)- γ, and interleukin (IL)- 2, IL-6,
IL-8, IL-12, and IL-15 and those in the Th2 immune response
are TNF-β, IL-4, IL-5, IL-9, IL-10, and IL-13 [16]. Pregnancy
hormones play a major role in mediating this bias towards the
Th2 profile by increasing the production of Th2 cytokines at
the maternal-fetal interface [49, 80].
As aforementioned, pregnancy is not a single event
of immune-suppression but rather a complicated scenar-
io of immunomodulation for maintaining the efficiency
of mother to eliminate the invading pathogens without
damaging the fetus. [62] aligned the immunological
phases of pregnancy with the stages of gestation such
as (1) first trimester and early second trimester, in
which there is active implantation and placentation, rep-
resent an immunological scenario of ‘wound healing’
and characterized by pro-inflammatory environment, (2)
second trimester and early third trimester represent an
immunological suppressive stage offering maternal-fetal
tolerance, and (3) terminal part of third trimester char-
acterized by revival of the pro-inflammatory condition
for the expulsion of fetus and placenta. EVs play crucial
roles in regulating and maintaining the maternal immune
response in every stage of gestation with definitive ef-
fect on the immune signaling in normal and complicated
pregnancies.
EVs in pregnancy and their effects
on maternal immune system
Several studies have evaluated the concentrations and origins
of circulating EVs in the maternal system and elucidated their
ability to interact with the immune cells and regulate them [28,
57, 71, 82]. Remarkably, pregnancy is characterized by higher
levels of circulating EVs than non-pregnant state and they
progressively increase with gestational age, achieving highest
concentration in the third trimester [65, 71, 79]. During early
stages of pregnancy, EVs derived from endometrium, embryo,
and trophoblast cells can influence the maternal immune re-
sponse, whereas towards the advanced stages of gestation, the
EVs released by the placenta, mainly STB-derived EVs, are
the key players (reviewed in [94]).
Four major sub-populations of EVs are derived from pla-
centa mainly the (1) exosomes (30–100 nm), (2) MVs
(100 nm–1 μm), also designated as STBMs, (3) syncytial
nuclear aggregates (20–500 μm), by which cells deport aging
nucleus in vesicles, and (4) apoptotic bodies (1–4 μm)
(reviewed in [86]). The deportation of STB-derived vesicles
into the maternal circulation has been recognized as an inte-
gral part of the normal turn-over mechanism of the trophoblast
cells but growing body of literature reveals that STB-derived
vesicles interact with the maternal immune system and their
alterations can be linked to adverse pregnancy outcomes
(reviewed in [15]). Apart from placental EVs, there is a vast
repertoire of EVs derived from maternal immune cells like
leucocytes and platelets eliciting significant impact on the
immunogenic, thrombogenic, and vascular mechanisms in
pregnancy [50, 51, 57]. Since the mechanism of biogenesis
is different for each sub-type of EVs, their function and effect
on the immune system vary between the sub-types. The
exosome and non-exosome EV populations from placenta dif-
fer significantly in their molecular cargo and impart different
effects on the maternal immune cells [67]. Hence, in this re-
view, we summarize the immune-modulatory properties of
EVs as two categories, firstly the immunomodulatory func-
tions of placental exosomes and secondly immunomodulatory
properties of STBMs in pregnancy.
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Placental exosomes
and their immunomodulatory
functions in pregnancy
The exosome secretion is a potential mechanism by which
placenta evades the cytotoxic effect of the maternal immune
system and modulates the immune-tolerance to the fetal pater-
n a l a n t i g en s . Ma j o r i t y o f t h e s t ud i e s f o r t h e
immune-modulatory effects of exosomes in pregnancy report
the immune-suppressive effects and its potential role in offer-
ing immune privilege for the developing fetus. Several immu-
nologically relevant proteins and molecules are reported to be
intimately associated with the exosome biogenesis and secret-
ed in the bioactive formwith exosomes. The expression of Fas
ligand (FasL) and TNF-related apoptosis-inducing ligand
(TRAIL) by the placental cells has been attributed to be an
important mechanism by which the local fetal tolerance is
developed. FasL and TRAIL are members of the TNF super-
family, mainly expressed in the STBs of placenta and mediate
apoptosis of the maternal lymphocytes at the feto-maternal
interphase. Interestingly, FasL and TRAIL are expressed ex-
clusively from MVBs originating from the endosomal com-
partments, whereas the apical and basal membranes of the
STBs are completely devoid of them. They are secreted in
the active form on the STB-derived exosomes and mediate
apoptosis of T cells and activated PBMCs offering
immunotolerance to fetus [25, 83].
Furthermore, ligands activating NKG2D receptors on NK
cellsandcytotoxicTcellsareexpressedandstoredinILVsarising
from the late endosomal compartments of STBs and secreted in
exosomes. These NKG2D ligands include the MHC Class
I-related antigenAandB (MICAandMICB) andULBPswhich
are GPI-linked glycoproteins belonging to the extended MHC
Class I family. TheNKG2D ligands activate theNKG2D recep-
tor inNKcells and cytotoxicTcellsmediating apoptosis of these
cells and consequent immune-suppression and local fetal toler-
ance [33].Theexpressionof these ligandson the surfaceofSTBs
is limited and the endosomal storage of immunologically active
ligand has been described as an integral mechanism of ligand
storage by the placental cells to mediate fetal immune-escape
via exosomes.
In addition to FasL, TRAIL, and NKG2D ligands, several
members of the B7 family of immune-regulatory ligands,
which bind to receptors in lymphocytes and mediate immune
response, are reported to co-localize with the exosome biosyn-
thetic machinery and released in the exosomes [43, 76].
Programmed death ligand-1 (PD-L1) is a member of B7 fam-
ily of immune-regulatory ligands, expressed on activated im-
mune cells including T cells and has major function in down-
regulating effector T cell activity and preventing
over-stimulation of the immune system [10]. Placental
exosomes express PD-L1 and mediate T cell suppression by
suppressing the CD3-zeta and JAK3 pathway [76]. Moreover,
B7-H1 is reported to be co-localizing with CD-63 in the
exosome biosynthetic pathway, and B7-H1 and B7-H3 have
been identified in the exosomes derived from explant cultures
of early and term placenta [43]. Further, immune-suppressant
molecule HLA-G is secreted with exosomes at early stages of
gestation and subsequently decreases with the progression of
pregnancy [43, 96]. Another immune-suppressant molecule
with potential effect on maternal system is the syncitin-1, an
endogenous retroviral envelop protein enriched in trophoblast
and mediating the trophoblast fusion leading to formation of
STBs. Specific protein motifs in the syncitin-1 limit it expres-
sion on the plasma membrane leading to early internalization
into endosomes by interaction with the TSG101 and ALIX
proteins and packaged into exosomes. Syncitin-1 expressed
in exosomes suppressed the production of TNF-α, IFN-γ,
and CXCL-10, presumably mediating the Th1 to Th2 shift
of cytokine profile in pregnancy [93].
Interestingly, exosome signaling in the maternal
immunomodulation involves not only the expression of mem-
brane proteins and ligand-receptor interactions, but also the
exosome-mediated delivery of immune-regulatory miRNAs
to recipient cells. The chromosome 19 miRNA cluster
(C19MC) is an imprinted primate-specific miRNA cluster
consisting of 46miRNAs and expressed exclusively in human
placenta (reviewed in [22]). The importance of C19MC for the
placentalphysiologyandmaternalhealth iscurrentlyunknown.
C19MC miRNAs, namely miR-512-3p and miR-517-3p are
carried by placenta-derived exosomes and transferred viral re-
sistance between trophoblast cells in a paracrine manner. The
suppressionofviral replicationby thesemiRNAswasmediated
by induction of autophagy [21]. Also, the miRNA,
miR-517a-3p carried by placental exosomeswhen internalized
byTcells andNKcells,was identified to target thePRKG1gene
which is involved in activation of nitric oxide/cGMP signaling
pathway,DownregulationofPRKG1gene inmaternal immune
cells regulates their activation and proliferation via the nitric
oxide/cGMP signaling pathway [38]. A further miRNA,
miR-141 carried by STB-derived exosomes, suppressed Tcell
proliferation and mediated the maternal tolerance to fetus.
miR-141 is reported tobeup-regulated inpre-eclampticplacen-
ta and involved in the pathophysiology of this condition [66].
In contrast to the immune-suppressive role of exosomes,
some reports illustrate the pro-inflammatory functions of
exosomes, in the spatial and temporal modulation of immune
system in pregnancy. STB-derived exosomes are reported to
increase the recruitment of monocytes from the maternal
system into the fetal-maternal interface and increase the
release of pro-inflammatory cytokines like IL-1β, IL-6,
serpin-E1, granulocyte/monocyte colony-stimulating fac-
tor, and TNF-α [8]. Fibronectin present on the exosomal
membrane binds to α5β1 integrin on the surface of mac-
rophage mediating this effect [9]. Additionally, trophoblast
cells themselves are capable of mounting specific
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immunological response to infections by internalizing the
exosomes derived from maternal macrophages by
c l a t h r i n - dependen t endocy t o s i s and r e l e a s i ng
pro-inflammatory cytokines [37]. This reveals the presence
of bi-directional trafficking mechanisms by which mater-
nal and fetal cells communicate for orchestrating the
immune-regulatory events in pregnancy.
Taken together, in pregnancy immune-suppressive func-
tions of exosomes play more pivotal roles in regulating the
maternal innate and adaptive immune response compared to
their pro-inflammatory effects. The immune-suppressive ef-
fects of pregnancy on many autoimmune diseases including
multiple sclerosis and autoimmune encephalomyelitis have
been attributed to exosome-mediated suppression of T cells
[27, 99]. Regarding placenta, exosome release from live and
active trophoblast cells is an integral method of signaling be-
tween the developing fetus and the maternal immune system
for achieving immune-tolerance. In contrast, the release of
STB-derived MVs and apoptotic bodies leads to activation
of the immune system and systemic inflammatory response.
STBMs and their immunomodulatory
functions in pregnancy
The STBs of placenta constitutively produce STBMs that can
interact with various target cells. It has been shown that
STBMs can potentially stimulate the maternal systemic in-
flammation by release of pro-inflammatory cytokines such
as TNF-α, IL-18, IL-12, and IFN-γ from circulating
leucocytes [28]. STBMs can activate monocytes in the mater-
nal system and increase the expression of adhesion molecule
CD54 inducing the release of pro-inflammatory cytokines like
IL-8, IL-6, and IL-1β [56]. Additionally, STBMs in the pres-
ence of IL-8 activated maternal neutrophils to produce neutro-
phil extracellular traps (NETs), which are extracellular DNA
containing fibrous lattices to capture extracellular bacteria [31,
32]. In addition, STBMs can affect the proliferation and apo-
ptosis of T cells by regulating the expression of IL-2 receptor
and STAT3 phosphorylation in T cells [68, 91]. The STB
fusion protein, syncytin-1, is expressed on the surface of
STBMs which on interaction with the maternal immune cells
can augment the release of pro-inflammatory cytokines but
dampen the response to LPS challenge [35].
[82] reported the ability of STBMs to release a variety of
cytokines like TNF-α , macrophage inflammatory
protein-1alpha (MIP-1α), IL-1α. IL-1β, IL-6, and IL-8 from
maternal immune cells mainly monocytes and B cells. They
reported the downregulation of cytokine IP-10 from maternal
immune cells indicating the skewing towards type 2 immuni-
ty. In this study, they obtained STBMs using differentmethods
and identified a similar cytokine profile with STMBs derived
from placental perfusion and explant culture but mechanically
derived STBMs exhibiting lesser stimulatory potential. The
impact of different STBM preparation on T cell activity was
evaluated by (Anurag Kumar [32]) and identified that me-
chanically and explant culture-derived STBMs inhibited Tcell
proliferation and cytokine production and perfusion-derived
STBMs induced T cell proliferation with IFN-γ release.
Hence, the experimental design used to isolate the STBMs
such as isolation of STBMs frommaternal plasma/serum, pla-
cental cell culture (primary and cell lines), placental perfusion,
placental explants, and mechanical derivation from placenta
have significant impact on the bioactivity of these vesicles.
The degree of tissue damage involved in each procedure
which determines the level of tissue necrosis and thereby the
quality of STBMs may be attributing these conflicting data
interpretations.
Finally, STBMs are important mediators of maternal sys-
temic inflammatory response by interacting with a variety of
immune cells. The precise mechanism by which STBM in-
duce systemic inflammatory response is being investigated in
depth. An exaggerated inflammatory response has been iden-
tified in several pregnancy disorders and a dysregulation in the
deportation of STMBs and apoptotic bodies has been impli-
cated as a key feature associated with complications in
pregnancy.
Immunomodulatory role of EVs
in pathological pregnancies
It has been well established that the EVs play critical roles in
the development and maintenance of successful pregnancy.
The concentration and bioactivity of EVs were altered in di-
verse pregnancy complications like PE, gestational diabetes
(GDM), pre-term birth (PTB), intra-uterine growth restriction
(IUGR), recurrent miscarriage, and unexplained pregnancy
loss [14, 39, 46, 54, 78, 88].
PE is a severe placenta-related disorder and a potentially
dangerous complication causing significant maternal and fetal
mortality [73]. The pathophysiology of PE involves a wide
range of clinical variants like poor placentation characterized
by defects in the spiral artery remodeling leading to placental
hypoxia, maternal hypertension, and proteinuria as well as
maternal thrombo-inflammatory dysregulation characterized
by alteration of cytokine profile and abnormal platelet activa-
tion leading to hypercoagulation [44, 73]. An enhanced pro-
duction of EVs is a classical feature of PE, contributing sig-
nificantly to its pathophysiology by modulating the
thrombo-inflammatory pathways in placenta [30].
Intriguingly, the STBEVs production in PE is reported to be
enhanced in some studies and diminished in others depending
on the experimental models used to evaluate the EV popula-
tion. The methods commonly used for the detection of
STBEVs are enzyme-linked immunosorbent assay (ELISA)
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Table 1 Studies reporting the immunomodulatory effects of placental exosomes in pregnancy
Study Experimental design for
isolation of exosomes
Methods of isolation of
exosome
Methods of characterization of
exosome
Findings
[83] Placental explant culture Differential and isopycnic
ultracentrifugation
EM, WB for CD63 Placental exosome carry FasL and
TRAIL and induce apoptosis in
T cells
[93] Placental explant culture
Primary trophoblast
culture
Trophoblast cell lines
Differential and isopycnic
ultracentrifugation
EM, WB for TSG 101 Syncytin-1 is present in placental
exosome and inhibit the
production of TH1 cytokines
[43] Primary trophoblast
culture
Placental explant culture
Differential and isopycnic
ultracentrifugation
EM, WB for CD63 Immunomodulatory molecules
such as HLA-G, B7-H1, and
B7-H3 are secreted with pla-
cental exosomes
[33] Placental explant culture Differential and isopycnic
ultracentrifugation
EM, WB for CD63 Exosomes bearing NKG2D
ligands (MIC and ULBPs) are
released by human placenta and
downregulate NKG2D receptors
in PBMCs
[66] Trophoblast cell lines Ultracentrifugation NTA miR-141 is packed into placental
EVs and is upregulated in PE.
miR-141 suppressed T cell pro-
liferation
[21] Primary trophoblast
culture
Trophoblast cell lines
Differential and isopycnic
ultracentrifugation
Not mentioned Placenta exosome-mediated trans-
fer of C19MC-associated
miRNAs confers viral resistance
in recipient cells
[99] In vivo (mice) Differential ultracentrifugation Not mentioned Serum exosomes mediate
pregnancy-associated suppres-
sion of autoimmune encephalitis
[38] Trophoblast cell lines Differential ultracentrifugation EM, WB for CD63, CD81, and
TSG101
Placenta-associated miRNA,
miR-517a-3p, targets PRKG1
gene in T cells and NK cells and
modulate the immune response
[76] Plasma/serum Size exclusion
chromatography and
ultracentrifugation
EM Placental exosome expressed FasL
and PD-L1 and suppressed T
cell signaling
[67] Primary trophoblast
culture
Plasma
Differential and isopycnic
ultracentrifugation
NTA, EM, WB for CD63,
syntenin-1, and TSG101
Placental exosome possesses a
distinct protein profile and more
potent anti-viral activity com-
pared to other placental EVs
[27] In vivo (in mice) Differential ultracentrifugation EM Circulating exosomes in pregnancy
suppress T cell activation
[65] Plasma/serum ExoQuick™ (System
Biosciences)
NTA, WB for Hsp70, ICAM-1,
CD9, CD63, CD81,and TSG101
Circulating EVs were higher in
pregnant women compared to
non-pregnant women. The ex-
pression of TGF-β1 and IL-10
were higher in EVs from preg-
nant women and enhanced the
caspase-3 activity in NK cells.
[3] Placental perfusion
Primary trophoblast
culture
Placental explant culture
Trophoblast cell lines
Differential and isopycnic
ultracentrifugation
NTA,WB for CD63 Trophoblast glycoprotein
(TPGB/5T4) is expressed in
placenta and STB-derived EVs
[8] Trophoblast cells Ultracentrifugation and
ultrafiltration
Not mentioned Placental exosomes recruit
monocytes and increase the
release of pro-inflammatory cy-
tokines
[9] Trophoblast cells Ultracentrifugation and
ultrafiltration
Not mentioned
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and flow cytometry. Studies using ELISA detects vesicles of
all sizes and reported an increase in STBEVs in PE, whereas
flow cytometry detects particles above 300 nm and found no
significant difference in placenta-derived EVs in PE. Hence,
particles below 300 nm, likely to be exosomes, could be po-
tentially contributing to this contradiction in data [29]. Also,
the molecular cargo of STBEVs varies considerably in PE
pregnancies with an augmented expression of tissue factor,
endoglin, and fms-like tyrosine kinase (Flt-1) which are key
mediators of pathological response in PE [85].
Additionally, STBEVs are reported to contribute to throm-
botic abnormalities in PE by activating platelets leading to its
aggregation [87] and ATP released from the activated platelets
activate purinergic-mediated NLRP3-inflammasome signal-
ing in the trophoblast cells leading to systemic inflammation
and endothelial dysfunction in PE [41]. Thus, pro-coagulant
EVs act as a functional link between coagulation and inflam-
mation in PE (reviewed in [40]). Elegant literature unveils the
interaction of STBEVs with maternal immune cells resulting
in a robust inflammatory response compared to healthy preg-
nancy [28, 37, 48]. The STBEVs activate the maternal im-
mune cells and elevate the expression of cytokines TNF-α,
IL-18, IL-1β, and IL-12p70 and dampens the IFN-γ produc-
tion. These alterations in cytokine profile are potential con-
tributors to inflammatory disorder in PE [28, 36].
STBEV-mediated exacerbated response to LPS and activation
of neutrophils leading to NET formation has been reported in
PE pregnancies [31, 32, 36].
Extracellular cues like hypoxia and glucose content have
significant impact on biosynthesis of EVs including exosome
(reviewed in [24]). Low oxygen concentrations increase the
release of EVs from trophoblast cells with alterations in the
bioactivity such as heightened release of inflammatory cyto-
kines, namely TNF-α and IL-6 as well as dampening the cell
migratory properties [48, 96]. Additionally, high glucose con-
centration is reported to impart similar effect by increasing
exosome release from trophoblast cells and promoting the
release of pro-inflammatory cytokines including IL-6 and
TNF-α from endothelial cells [75]. Further, this impact of
high glucose concentration in vitro has been recapitulated
in vivo in GDM pregnancies [78]. A significant proportion
(nearly 12–25%) of the total circulating exosomes in
mother has been contributed by placental exosomes and
a strong correlation between exosome release and maternal
BMI has been revealed with exosomes from obese
mothers releasing more IL-6, IL-8, and TNF-α from en-
dothelial cells (HUVEC) [23].
In contrast, PTB pregnancies exhibited a 1.8-fold lesser
concentration of exosomes than full-term pregnancies follow-
ed by a greater suppression of CD3-zeta and JAK3 pathways
mediating immunotolerance to growing fetus [88]. Hence,
concentration as well as the bioactivity of EVs in pregnancy
is a crucial mediator of cell signaling and immunomodulation
in pathological conditions. In general, exosomes derived from
placenta are immunosuppressive and placental non-exosomal
vesicles like STBMs are inflammatory in their bioactivity.
This prompted [58] to suggest an optimal ratio between
STBMs and exosomes in normal pregnancy is > 1 and
skewing to a higher level culminates in pathological pregnan-
cies and other abnormalities. A summary of the studies on
Table 1 (continued)
Study Experimental design for
isolation of exosomes
Methods of isolation of
exosome
Methods of characterization of
exosome
Findings
Placental exosome-associated fi-
bronectin induces release of
IL-1β from macrophages
[75] First-trimester primary
trophoblast cells
Differential and isopycnic
ultracentrifugation
NTA, EM, WB (CD 63) High glucose concentrations
increase the release of placental
exosomes
[78] Plasma Differential and isopycnic
ultracentrifugation
NTA, EM, WB (CD 63) Placental exosome concentration is
increased in GDM. GDM
exosomes increased the release
of pro-inflammatory cytokines
from endothelial cells.
[96] Trophoblast cell lines Differential and isopycnic
ultracentrifugation
NTA, EM, WB for TSG101 Exosome release from placenta is
increased with hypoxia and
hypoxic exosomes decrease
endothelial cell migration and
increase TNF-α release
[23] Plasma Differential and isopycnic
ultracentrifugation
NTA, EM, WB for CD63 Maternal BMI affects the
concentration and bioactivity of
circulating exosomes
EM electron microscopy, WBWestern blot, NTA nanoparticle tracking analysis
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EVs and immunoregulation during gestation is presented in
the Table 1.
Conclusion and future perspectives
A schematic representation of the role of exosomes during
pregnancy is presented in the Fig. 2. There has been immense
research interest in the elucidation of cell signaling mediated
by EVs in pregnancy and evaluation of their diagnostic and
therapeutic utility. But the progress in this area has been hin-
dered by a lack of standardized protocols that can efficiently
isolate and characterize pure populations of different
sub-populations of EVs. Majority of studies on placental
exosomes used ultracentrifugation followed by density gradi-
ent centrifugation for isolation and characterized the vesicles
based on their size below 150 nm, cup-shaped morphology on
electron microscopy, and presence of endosomal markers like
tetraspanins, Tsg101, and ALIX, whereas large number of
studies on STMBs isolated them by ultracentrifugation and
evaluated their surface markers using flow cytometry or
ELISA. Since these protocols enrich a vesicle sub-type and
do not eliminate completely other vesicle types, this can lead
to some over-lap in the biological functions reported for these
vesicles. A better understanding of the biogenetic mechanism
of these vesicles could aid in a precise delineation of their
markers paving way for accurate interpretation of their bio-
logical functions.
Growing evidences show that placental EVs can interact
with a multitude of maternal immune cells and influence their
function. The bioactivity of EVs on the target cells and poten-
tial effect on the maternal immune system depends on the
quality of EV preparation. Several experimental designs like
isolation of EVs from biological fluids, in vitro placental pri-
mary cells and cell lines, placental explants, perfusions, and
mechanical derivation from placenta have been employed.
The population of EVs as well as their biological activity
varies considerably with the experimental model used and
gives conflicting results under certain conditions. Hence, the
experimental variability attributed by experimental models
Fig. 2 Schematic representation of immunomodulatory effects of
placental exosomes and STBMs on maternal immune system. Immune-
suppressive ligands such as FasL, TRAIL, NKG2D, and PDL-1 are pres-
ent on the exosomal membrane and regulate apoptosis and cytotoxicity of
maternal leucocytes. Exosome mediates pro-inflammatory effect by re-
cruitment and activation of monocytes. STBMs mediates systemic in-
flammatory response in pregnancy by activating the maternal leucocytes
to release pro-inflammatory cytokines
Semin Immunopathol
should be considered while interpreting the functional activity
of EVs. Additionally, majority studies reported the effect of
EVs by in vitro inoculation with PBMCs and analyzing the
downstream effect. This does not essentially recapitulate the
in vivo situation. We believe that in vivo inoculation can give
a better understanding of specific targeting of EVs and their
precise biological function in the body. Finally, current litera-
ture predominantly evaluates the immunomodulatory proteins
in EVs, but understanding the vital roles of other EV contents
like regulatory RNAs can provide further insights into this
area of research.
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